NovoCure Ltd. NVCR

BAAR, Switzerland, October 01, 2026--Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

BAAR, Switzerland, October 01, 2026--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.

NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...